Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States.

Biotechnology

Health Care

Therapeutics

Sapience Therapeutics, Inc.

Barry Kappel

Seth Rubin

Nancy Dong, CMA, SPHR

Marisa Frackman

Jim Rotolo

Gina Capiaux

Gene Merutka

Dana Porrazzo

The Research and Development Team at Sapience Therapeutics is dedicated to innovating and advancing preclinical drug candidates targeting high mortality cancers, particularly glioblastoma multiforme. This team collaborates on experimental design, conducts rigorous laboratory research, and utilizes cutting-edge methodologies to translate scientific discoveries into effective therapeutic strategies, ultimately aiming to address significant unmet medical needs in oncology.

Research and Development Team

Leadership Team

Research and Development Team

About

Team members

Other teams at Sapience Therapeutics, Inc.

Leadership Team